A Cooperative Agreement for the Interstitial Cystitis Association To Develop and Implement a Program To Enhance Interstitial Cystitis Public and Health Provider Awareness Through Partnership, Education and Communication; Notice of Intent To Fund Single Eligibility Award, 43693-43694 [05-14927]
Download as PDF
Federal Register / Vol. 70, No. 144 / Thursday, July 28, 2005 / Notices
containing copyrighted material, EPA
will provide a reference to that material
in the version of the comment that is
placed in EPA’s electronic public
docket. The entire printed comment,
including the copyrighted material, will
be available in the official public
docket.
Public comments submitted on
computer disks that are mailed or
delivered to the EPA Docket Center will
be transferred to E-Docket. Public
comments that are mailed or delivered
to the EPA Docket Center will be
scanned and placed in E-Docket. Where
practical, physical objects will be
photographed, and the photograph will
be placed in E-Docket with a brief
description written by the docket staff.
You may submit comments
electronically, by mail, by facsimile, or
by hand delivery/courier. To ensure
proper receipt by EPA, include the
appropriate docket identification
number with your submission. Please
ensure that your comments are
submitted within the specified comment
period. Comments received after the
closing date will be marked ‘‘late,’’ and
may only be considered if time permits.
If you submit comments
electronically, EPA recommends that
you include your name, mailing
address, and an e-mail address or other
contact information in the body of your
comment. Also include this contact
information on the outside of any
submitted disk or CD–ROM, and in any
cover letter accompanying the disk or
CD–ROM. This ensures that you can be
identified as the person submitting the
comment and allows EPA to contact you
in case the Agency cannot read your
submission due to technical difficulties
or needs further information on the
substance of your comment. EPA will
not edit your comment, and any
identifying or contact information
provided in the body of a comment will
be included as part of the comment that
is placed in the official public docket
and made available in E-Docket. If EPA
cannot read your comment due to
technical difficulties and cannot contact
you for clarification, it may delay or
preclude consideration of your
comment.
Electronic submission of comments to
E-Docket is EPA’s preferred method for
receiving comments. Go directly to EPA
Dockets at https://www.epa.gov/edocket,
and follow the online instructions for
submitting comments. To access EPA’s
electronic public docket from the EPA
Internet Home Page, select ‘‘Information
Sources,’’ ‘‘Dockets,’’ and ‘‘EPA
Dockets.’’ Once in the system, select
‘‘search,’’ and then key in Docket ID No.
ORD–2005–0022. The system is an
VerDate jul<14>2003
13:40 Jul 27, 2005
Jkt 205001
‘‘anonymous access’’ system, which
means EPA will not know your identity,
e-mail address, or other contact
information unless you provide it in the
body of your comment.
Comments may be sent by electronic
mail (e-mail) to ORD.Docket@epa.gov,
Attention Docket ID No. ORD–2005–
0022. In contrast to EPA’s electronic
public docket, EPA’s e-mail system is
not an ‘‘anonymous access’’ system. If
you send an e-mail comment directly to
the docket without going through EPA’s
E-Docket, EPA’s e-mail system
automatically captures your e-mail
address, and it becomes part of the
information in the official public docket
and in E-Docket.
You may submit comments on a disk
or CD–ROM that you mail to the OEI
Docket mailing address. Files will be
accepted in WordPerfect, Word, or PDF
format. Avoid the use of special
characters and any form of encryption.
If you provide comments in writing,
please submit one unbound original
with pages numbered consecutively,
and three copies of the comments. For
attachments, provide an index, number
pages consecutively with the comments,
and submit an unbound original and
three copies.
43693
PERSON TO CONTACT FOR INFORMATION:
Mr. Robert Biersack, Press Officer,
telephone: (202) 694–1220.
Mary W. Dove,
Secretary of the Commission.
[FR Doc. 05–15068 Filed 7–26–05; 2:30 pm]
BILLING CODE 6715–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Program Announcement AA173]
A Cooperative Agreement for the
Interstitial Cystitis Association To
Develop and Implement a Program To
Enhance Interstitial Cystitis Public and
Health Provider Awareness Through
Partnership, Education and
Communication; Notice of Intent To
Fund Single Eligibility Award
Sunshine Act Notices
A. Purpose
The Centers for Disease Control and
Prevention (CDC) announces the intent
to fund fiscal year (FY) 2005 funds for
a cooperative agreement program to
promote public awareness and
partnership, provide interstitial cystitis
(IC) education for the general public and
for health care providers, and develop
and enhance communication channels
to allow for improved interaction and
information sharing among those with
IC, advocates for persons with IC and
their families, those who provide care
and services for persons with IC,
researchers, public health scientists, and
the general public. The Catalog of
Federal Domestic Assistance number for
this program is 93.283.
Federal Election Commission.
PREVIOUSLY ANNOUNCED DATE AND TIME:
Thursday, July 21, 2005, 10 a.m.
Meeting open to the public. This
meeting was cancelled.
PREVIOUSLY ANNOUNCED DATE AND TIME:
Thursday, July 28, 2005, 10 a.m.
Meeting open to the public. This
meeting was cancelled.
DATE AND TIME: Thursday, August 4,
2005, at 10 a.m.
PLACE: 999 E Street, NW., Washington,
DC (Ninth Floor).
STATUS: These hearings will be open to
the public.
MATTERS BEFORE THE COMMISSION:
(1) State, District, and Local Party
Committee Payment of Certain Salaries
and Wages;
(2) Definition of Federal Election
Activity.
B. Eligible Applicant
Assistance will be provided only to
Interstitial Cystitis Association, 110 N.
Washington Street, Suite 340, Rockville,
MD 20850.
Founded in 1984, The Interstitial
Cystitis Association (ICA) is a not-forprofit health organization and the
national leader dedicated to providing
patient and physician educational
information and programs, patient
support, public awareness and, most
importantly, research funding for IC.
ICA is the only not-for-profit national IC
organization that promotes and provides
funding for much needed IC research.
This characteristic of ICA’s organization
is unmatched by any other public or
private IC health organization currently
conducting similar activities in the
United States. The primary mission of
ICA is to research a cure and treatment
for IC and provide information and
Dated: July 22, 2005.
Peter W. Preuss,
Director, National Center for Environmental
Assessment.
[FR Doc. 05–14932 Filed 7–27–05; 8:45 am]
BILLING CODE 6560–50–P
FEDERAL ELECTION COMMISSION
AGENCY:
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
E:\FR\FM\28JYN1.SGM
28JYN1
43694
Federal Register / Vol. 70, No. 144 / Thursday, July 28, 2005 / Notices
assistance to patients, doctors, and the
general public.
The ICA has over 20 years of
achievement unmatched by any other
health organization dealing with IC
issues. Some of these achievements
include:
• Public awareness—the ICA has
consistently attracted media attention to
IC. Numerous articles featuring IC and
the ICA have been published from the
‘‘New York Times,’’ ‘‘SELF Magazine,’’
‘‘Good Housekeeping,’’ and many other
national magazines. Subject-matter
experts from the ICA have appeared on
national TV and radio programs to
include ABC’s ‘‘Good Morning
America,’’ CNN, and National Public
Radio.
• Physician and Patient Education—
Subject-matter experts from the ICA
have published numerous articles on IC
for professional journals including
‘‘Urology’’ and the ‘‘World Journal of
Urology.’’ The ICA has worked closely
with the NIDDK Division of Urology for
over 15 years and has co-sponsored with
the NIDDK, international scientific
conferences as well as national IC
patient meetings on IC biannually. ICA
has also sponsored numerous regional
educational programs for patients
throughout the United States each year.
• Patient Support—The ICA provides
a toll-free 800 number designed to
quickly assist both IC patients and
healthcare providers. ICA also provides
nationwide individual support via
telephone and e-mail by ICA National
Patient Support Advocates; the
International IC Question Corner on its
Web site, where patients can e-mail the
ICA and receive one-on-one assistance
with their questions; the ICA Physician
Registry which helps IC patients find ICknowledgeable physicians; and IC
connections, which brings together
patients based on specific interests,
concerns and regions, and an
informational program on how to start
new IC support groups.
• Innovative resources—the ICA
published, and continues to regularly
update, a series of brochures and fact
sheets as well as ‘‘IC Treatment
Guidelines’’—the first comprehensive
summary of IC treatments and
medications designed for patients and
their physicians for use as the basis for
an individualized treatment plan. The
ICA also publishes an on-line monthly
´
news digest, ‘‘Cafe ICA,’’ and two
quarterly newsletters—the ‘‘ICA
Update,’’ the only printed newsletter on
IC in the United States, and the ‘‘ICA
Physician Perspectives.’’ ICA also
publishes a ‘‘Pocket Guide’’ series for
continuing patient education.
VerDate jul<14>2003
13:40 Jul 27, 2005
Jkt 205001
• Comprehensive Web Site—The
ICA’s Web site https://www.icahelp.org,
established in 1995, is the most
comprehensive Web site on IC available
today, receiving over 1.4 million hits
per month. The site includes: a Clinical
trials section, their on-line monthly
´
news digest—‘‘Cafe ICA,’’ IC Question
Corner which provides one-on-one
patient support, Treatment Options, a
section for health care providers, a
comprehensive research section, and
much more * * *.
• Non-profit leadership—the ICA
remains the only United States 501
(c)(3) registered non-profit organization
to fund IC research and provide
educational programs on IC for both
physicians and patients, as well as the
public at large.
This mission and ICA’s extensive
network of resources and record of
unmatched achievements over the last
20 years, makes it highly probable that
ICA will successfully implement and
complete all the required activities for
this program announcement. For these
reasons, the ICA is the only organization
being considered for this program
announcement.
C. Funding
Approximately $ 510,000 is available
in FY 2005 to fund this award. It is
expected that the award will begin on or
before September 1, 2005, and will be
made for a 12-month budget period
within a project period of up to five
years. Funding estimates may change.
D. Where To Obtain Additional
Information
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director,
Centers for Disease Control and
Prevention
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following Advisory
Committee meeting.
Name: Advisory Committee to the Director,
CDC.
Time and Date: 8:30 a.m.–4:30 p.m.,
August 25, 2005.
Place: Emory Conference Center, 1615
Clifton Road, Atlanta, Georgia 30329.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 75 people.
Purpose: The committee will provide
advice to the CDC Director on strategic and
other broad issues facing CDC.
Matters to Be Discussed: Agenda items will
include updates on CDC priorities with
discussions of program activities including
updates on CDC scientific and programmatic
activities, strategic imperatives, goals,
research agenda, and health equity.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Robert Delaney, Executive Secretary,
Advisory Committee to the Director, CDC,
1600 Clifton Road, NE, M/S D–14, Atlanta,
Georgia 30333. Telephone (404) 639–7000.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
For general comments or questions
about this announcement, contact:
Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341–4146; telephone: 770–488–2700.
For technical questions about this
program, contact: Richard S. Roman,
Project Officer, HCAS/DACH/
NCCDPHP/CDC, 4770 Buford Hwy.,
N.E., MS K–51, Chamblee, GA 30341;
telephone: 770–488–5144; e-mail:
rsr1@cdc.gov.
Dated: July 25, 2005.
Diane Allen,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 05–15019 Filed 7–27–05; 8:45 am]
Dated: July 22, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–14927 Filed 7–27–05; 8:45 am]
Proposed Vaccine Information
Materials for Hepatitis A and Influenza
Vaccines; Interim Vaccine Information
Materials for Influenza Vaccines
BILLING CODE 4163–18–P
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
E:\FR\FM\28JYN1.SGM
28JYN1
Agencies
[Federal Register Volume 70, Number 144 (Thursday, July 28, 2005)]
[Notices]
[Pages 43693-43694]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14927]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement AA173]
A Cooperative Agreement for the Interstitial Cystitis Association
To Develop and Implement a Program To Enhance Interstitial Cystitis
Public and Health Provider Awareness Through Partnership, Education and
Communication; Notice of Intent To Fund Single Eligibility Award
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
intent to fund fiscal year (FY) 2005 funds for a cooperative agreement
program to promote public awareness and partnership, provide
interstitial cystitis (IC) education for the general public and for
health care providers, and develop and enhance communication channels
to allow for improved interaction and information sharing among those
with IC, advocates for persons with IC and their families, those who
provide care and services for persons with IC, researchers, public
health scientists, and the general public. The Catalog of Federal
Domestic Assistance number for this program is 93.283.
B. Eligible Applicant
Assistance will be provided only to Interstitial Cystitis
Association, 110 N. Washington Street, Suite 340, Rockville, MD 20850.
Founded in 1984, The Interstitial Cystitis Association (ICA) is a
not-for-profit health organization and the national leader dedicated to
providing patient and physician educational information and programs,
patient support, public awareness and, most importantly, research
funding for IC. ICA is the only not-for-profit national IC organization
that promotes and provides funding for much needed IC research. This
characteristic of ICA's organization is unmatched by any other public
or private IC health organization currently conducting similar
activities in the United States. The primary mission of ICA is to
research a cure and treatment for IC and provide information and
[[Page 43694]]
assistance to patients, doctors, and the general public.
The ICA has over 20 years of achievement unmatched by any other
health organization dealing with IC issues. Some of these achievements
include:
Public awareness--the ICA has consistently attracted media
attention to IC. Numerous articles featuring IC and the ICA have been
published from the ``New York Times,'' ``SELF Magazine,'' ``Good
Housekeeping,'' and many other national magazines. Subject-matter
experts from the ICA have appeared on national TV and radio programs to
include ABC's ``Good Morning America,'' CNN, and National Public Radio.
Physician and Patient Education--Subject-matter experts
from the ICA have published numerous articles on IC for professional
journals including ``Urology'' and the ``World Journal of Urology.''
The ICA has worked closely with the NIDDK Division of Urology for over
15 years and has co-sponsored with the NIDDK, international scientific
conferences as well as national IC patient meetings on IC biannually.
ICA has also sponsored numerous regional educational programs for
patients throughout the United States each year.
Patient Support--The ICA provides a toll-free 800 number
designed to quickly assist both IC patients and healthcare providers.
ICA also provides nationwide individual support via telephone and e-
mail by ICA National Patient Support Advocates; the International IC
Question Corner on its Web site, where patients can e-mail the ICA and
receive one-on-one assistance with their questions; the ICA Physician
Registry which helps IC patients find IC-knowledgeable physicians; and
IC connections, which brings together patients based on specific
interests, concerns and regions, and an informational program on how to
start new IC support groups.
Innovative resources--the ICA published, and continues to
regularly update, a series of brochures and fact sheets as well as ``IC
Treatment Guidelines''--the first comprehensive summary of IC
treatments and medications designed for patients and their physicians
for use as the basis for an individualized treatment plan. The ICA also
publishes an on-line monthly news digest, ``Caf[eacute] ICA,'' and two
quarterly newsletters--the ``ICA Update,'' the only printed newsletter
on IC in the United States, and the ``ICA Physician Perspectives.'' ICA
also publishes a ``Pocket Guide'' series for continuing patient
education.
Comprehensive Web Site--The ICA's Web site https://
www.icahelp.org, established in 1995, is the most comprehensive Web
site on IC available today, receiving over 1.4 million hits per month.
The site includes: a Clinical trials section, their on-line monthly
news digest--``Caf[eacute] ICA,'' IC Question Corner which provides
one-on-one patient support, Treatment Options, a section for health
care providers, a comprehensive research section, and much more * * *.
Non-profit leadership--the ICA remains the only United
States 501 (c)(3) registered non-profit organization to fund IC
research and provide educational programs on IC for both physicians and
patients, as well as the public at large.
This mission and ICA's extensive network of resources and record of
unmatched achievements over the last 20 years, makes it highly probable
that ICA will successfully implement and complete all the required
activities for this program announcement. For these reasons, the ICA is
the only organization being considered for this program announcement.
C. Funding
Approximately $ 510,000 is available in FY 2005 to fund this award.
It is expected that the award will begin on or before September 1,
2005, and will be made for a 12-month budget period within a project
period of up to five years. Funding estimates may change.
D. Where To Obtain Additional Information
For general comments or questions about this announcement, contact:
Technical Information Management, CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA 30341-4146; telephone: 770-488-2700.
For technical questions about this program, contact: Richard S.
Roman, Project Officer, HCAS/DACH/NCCDPHP/CDC, 4770 Buford Hwy., N.E.,
MS K-51, Chamblee, GA 30341; telephone: 770-488-5144; e-mail:
rsr1@cdc.gov.
Dated: July 22, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention.
[FR Doc. 05-14927 Filed 7-27-05; 8:45 am]
BILLING CODE 4163-18-P